Investment deals (institutional investors only)

Deciduous Therapeutics

Deciduous Therapeutics has discovered novel molecules that can activate a critical endogenous …

Therapeutics San Francisco, US
  • Raising
    $12,000,000
  • Stage
    Seed
BrainKey

BrainKey analyzes your MRI, genetic and demographic data to learn more about …

Digital Health San Francisco, US
  • Raising
    -
  • Stage
    -
Occuity

Occuity has developed a range of innovative non-contacting devices that can track …

Medical Device Reading, UK
  • Raising
    £5,000,000
  • Stage
    Series A
TruDiagnostic

TruDiagnostic is first to market with a single, comprehensive multi-omics test, replacing …

Diagnostics Lexington, US
  • Raising
    $5,000,000
  • Stage
    Series A
Yuva Biosciences

Yuva Biosciences uses a unique discovery and development platform with proprietary mouse …

Therapeutics Birmingham, US
  • Raising
    $2,000,000
  • Stage
    Seed

Investment briefing 〉

Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Managing senescent cells to drive human longevity:
Senotherapeutics
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now

News >>

Certific and PocDoc collaborate to tackle cardiovascular disease

Healthtech startups announce a partnership to tackle world’s biggest killer with novel…

Eye-level longevity – why breakthrough research is top investment opportunity

Our pioneers of longevity discuss where the field can be monetised and…

New $100 million longevity fund puts the spotlight on software

LifeX Ventures co-founder on the relevance of software at every layer of…

We might not know the future… but we can spot its longevity trends and drivers

Ahead of the Longevity Investors Conference, our longevity hivemind talks biomarkers, translation…

Company alerts >>

  • September 26, 2022
    Recursion’s
    Recursion Pharmaceuticals
    Also known as: #N/A
    LT 2362
    362 of 560
    Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
    Longevity pillar
    • Treatment
    • Prevention
    Longevity domain:
    • Discovery platforms
    Location: United States
    Year founded: 05-Nov-13
    Longevity target: Aging Disease, Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    multi-year, strategic collaboration with Roche and Genentech.
  • September 23, 2022
    Gameto
    Gameto
    Also known as: Gameto
    LT 2174
    174 of 560
    Gameto wants to synchronize the pace of ovarian aging to the rate of aging in other organs such as the liver, brain, or skin. When ovaries are termed “geriatric” by many traditional medical criteria, the rest of the body is certainly not and this creates conflict for people pushing them to make compromises they may not wish to make. Considering human healthspan and lifespan have increased significantly, Gameto believes this biological phenomenon is no longer fit for purpose and is a problem worth solving. The scientific work involves reconstituting ovarian development and function in vitro, elucidating the underlying growth factor and genetic networks that drive human ovarian development and oogenesis.
    Longevity pillar
    • Prevention
    • Renewal
    Longevity domain:
    • Reproductive longevity
    Location: United States
    Year founded: 01-Jan-20
    Longevity target: Aging Disease, Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    is raising $26,999,944.00 in new equity investment.
  • September 23, 2022
    BioChange
    BioChange ltd
    Also known as: #N/A
    LT 2059
    59 of 560
    BioChange has developed a breakthrough technology for tissue regeneration. A unique injectable scaffold that stimulates tissue repair and remodelling at the injected site. The scaffold is based on natural biomaterials designed for implantation using a minimally invasive procedure. It mimics the healthy Extra Cellular Matrix (ECM) and triggers the body to repair itself. Multiple long-term animal studies confirmed the safety and efficacy of the technology. The company is now selling products in the veterinary market and in tissue engineering research and is committed to start first clinical study in aesthetic dermatology in 2022.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    Location: Israel
    Year founded: 01-Jun-16
    Longevity target: Aging Disease
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    develops a breakthrough technology for tissue regeneration to treat periodontitis.
  • September 22, 2022
    Longevica
    Longevica
    Also known as: #N/A
    LT 2252
    252 of 560
    Longevica is a life science company researching the mechanisms of healthy aging and life extension. Longevica harnesses objective scientific research, clinical studies, research collaboration, and technology to develop novel, proactive therapeutic interventions to improve health and quality of life, prevent age-related disease, and facilitate the productive extension of lifespan.
    Longevity pillar
    • Prevention
    Longevity domain:
    • Repurposed Drugs
    • Discovery platforms
    Location: United States
    Year founded: 01-Jan-08
    Longevity target: Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    raised $0.18mn in Later Stage VC funding.
  • September 22, 2022
    Cumulus Neuroscience
    Cumulus Neuroscience
    Also known as: Cumulus
    LT 2118
    118 of 560
    Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients.
    Longevity pillar
    • Treatment
    Longevity domain:
    • Discovery platforms
    • Neurotech
    Location: United Kingdom
    Year founded: 05-Jan-15
    Longevity target: Aging Disease
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    appoints Aman Bhatti, MD as CEO.
  • September 21, 2022
    Occuity
    Occuity
    Also known as: #N/A
    LT 2328
    328 of 560
    Occuity is developing solutions to some of humanity’s greatest health challenges through the invention of optical diagnostic technologies, to bring pain-free, non-contact screening & monitoring of chronic health conditions such as glaucoma, myopia, diabetes and Alzheimer’s Disease
    Longevity pillar
    • Diagnostic
    Longevity domain:
    • Longevity diagnostics
    Location: United Kingdom
    Year founded: 06-Sep-19
    Longevity target: Aging Disease
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of September 27, 2022
    secures Department for Trade funding.